|
|
|
|
Vol. 18, Issue 4, 1437-1446, April 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Pharmacology and Cancer Biology, Department of Immunology, and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27710
Submitted July 11, 2006;
Revised December 22, 2006;
Accepted February 2, 2007
Monitoring Editor: Ben Margolis
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
In hematopoietic cells, growth factors such as the cytokines interleukin (IL)3 or IL7 can provide critical signals to promote glucose uptake (Kan et al., 1994
; Rathmell et al., 2001
; Bentley et al., 2003
). Glucose uptake is controlled via a family of facilitative glucose transporters that has been best characterized by the insulin-mediated regulation of Glut4 trafficking in muscle and adipose tissues (Watson et al., 2004
). Hematopoietic cells instead rely on the ubiquitous glucose transporter Glut1 as a primary source for intracellular glucose (Rathmell et al., 2000
). Glut1 synthesis is cytokine-dependent, with loss of Glut1 mRNA and surface protein levels when cells are cytokine-deprived (Rathmell et al., 2000
; Vander Heiden et al., 2001
; Bentley et al., 2003
). Glut1 trafficking can also be regulated, because insulin signaling has been shown to promote Glut1 translocation to the cell surface (Piper et al., 1991
). Although growth factor-stimulated synthesis of Glut1 has been shown to affect surface Glut1 levels in hematopoietic cells (Plas et al., 2002
; Rathmell et al., 2003
), a role for noninsulin growth factors in regulation of Glut1 activity and trafficking has not yet been directly determined.
Several mechanisms may promote cytokine-mediated regulation of Glut1 trafficking. First, phosphatidylinositol 3-kinase (PI3K) and its downstream effector kinase Akt/PKB have a well-established role in Glut4 vesicle trafficking to the cell membrane in response to insulin (Welsh et al., 2005
). Likewise, the cytokines IL3 and IL7 can activate Akt in hematopoietic cells (Plas et al., 2002
), and we have shown by immunofluorescence and biochemical fractionation that an activated and oncogenic form of Akt can promote accumulation of Glut1 on the surface of lymphoid cells even in the absence of cytokine (Plas et al., 2001
; Rathmell et al., 2003
). The mechanism of this regulation is unknown, but Akt may increase Glut1 protein synthesis (Barthel et al., 1999
; Plas et al., 2001
). Alternatively, Akt activation of mammalian target of rapamycin (mTOR)/regulatory associated protein of mTOR (RAPTOR) (mTOR/RAPTOR) has been shown to regulate trafficking of the transferrin receptor (TfR), low-density lipoprotein (LDL) receptor, and the amino acid transporter 4F2 (Edinger and Thompson, 2002
). The Akt substrate glycogen synthase kinase (GSK3) may also regulate Glut1 trafficking, because it has been recently shown to control integrin recycling (Roberts et al., 2004
).
To better understand how growth factor or oncogenic stimulation may promote glucose uptake, we have directly analyzed cytokine-mediated regulation of Glut1 in lymphoid/myeloid hematopoietic precursor cells. Here, we show that the hematopoietic growth factor IL3 promotes glucose uptake in part by promoting localization and retention of Glut1 on the cell surface. IL3 receptor engagement attenuated Glut1 internalization, and this activity required Rab11a to promote maximal surface levels, suggesting IL3 regulation of Glut1 endocytosis and recycling. IL3-induced activation of PI3K, and Akt was found to be necessary and sufficient to regulate Glut1 activity and trafficking. These data directly demonstrate that Glut1 activity, recycling, and internalization are regulated aspects of growth factor-stimulated glucose uptake in hematopoietic cells and implicate Akt as an important mediator of each of these processes.
| MATERIALS AND METHODS |
|---|
|
|
|---|
S9A was generously provided by Dr. Xiao-Fan Wang (Duke University).
Cells
The early hematopoietic myeloid/lymphoid cell line FL5.12 was cultured as described previously (Vander Heiden et al., 1997
) with addition of recombinant murine IL3 (500 pg/ml; Peprotech, Rocky Hill, NJ). Inhibitors included the following: for protein synthesis, 10 µg/ml cycloheximide (CHX) (Sigma-Aldrich, St. Louis, MO); for PI3K, 10 µM LY294002 (Calbiochem, San Diego, CA); for mTOR/RAPTOR, 25 nM rapamycin (Calbiochem); and for GSK3, 10 µM SB216763, 20 µM SB415286, or 10 µM AR-A0144-18 (Sigma-Aldrich). Cells with inducible myrAkt have been described previously (Plas et al., 2001
) or were generated by transient transfection of FL5.12 cells with myrAkt1 in pEF6.
2-Deoxy-D-glucose (2-DOG) Transport Assay
Glucose uptake was measured as described previously with small modifications (Bentley et al., 2003
; Rathmell et al., 2003
). Cells were washed and resuspensed in Krebs-Ringer-HEPES (KRH) (at pH 7.4, 136 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.25 mM MgSO4, and 10 mM HEPES). 2-Deoxy-D-[H3]glucose (2 µCi/reaction) was added for a period of either 1 or 5 min at 37°C. Reactions were quenched by addition of ice-cold 200 µM phloretin (Calbiochem) and centrifugation through an oil layer (1:1 Dow Corning 550 Silicon fluid [Motion Industries, Birmingham, AL] and dinonyl phthalate [Sigma-Aldrich]). The cell pellet was washed and solubilized in 1 M NaOH, and radioactivity was measured with scintillation counter.
Surface Glut1 Measurement and Flow Cytometry
Cells were analyzed by a FACscan (BD Biosciences, San Jose, CA) and FlowJo software (Tree Star, Inc., Ashland, OR). To determine FLAG surface expression, cells were washed once in phosphate-buffered saline (PBS)/2% fetal bovine serum (FBS). Cells were blocked with anti-Fc
III/II (BD Biosciences PharMingen, San Diego, CA) and incubated with 5% rat serum and rabbit anti-FLAG (Sigma-Aldrich) followed by R-Phycoerythrin donkey anti-rabbit (Jackson ImmunoResearch, West Grove, PA) for analysis. Surface FLAG-Glut1 levels were normalized to total FLAG expression by division of the mean fluorescence of surface FLAG by the average pixel density from respective immunoblot. To determine TfR (CD71) surface expression, cells were incubated with anti-mouse CD71-PE (BD Biosciences PharMingen). For pulse-chase assays, cells were blocked with anti-Fc
III/II (BD Biosciences PharMingen) for 5 min followed by a pulse with anti-FLAG antibody (Sigma-Aldrich) at room temperature for 10 min, washed, and cultured for various periods at 37°C before addition of secondary stain on ice. Mean fluorescence of cell surface Glut1 levels were normalized to the starting value.
Fluorescence Microscopy
Cells were transfected with GFP-Glut1 and fixed with 1% paraformaldehyde in PBS and viewed with a Zeiss LSM410 confocal microscope (Carl Zeiss, Thornwood, NY) and MetaMorph software (Molecular Devices, Sunnyvale, CA).
Immunoblotting
Cells were lysed for Western blotting for 1 h on ice in 1% Triton and 0.1% SDS in PBS with protease inhibitors (BD Biosciences PharMingen) and precleared by centrifugation. Equivalent protein concentrations were loaded on a 415% SDS-polyacrylamide gel electrophoresis gel (Bio-Rad, Hercules, CA). Primary antibodies used were anti-FLAG M2 peroxidase (Sigma-Aldrich), rabbit anti-Glut1 (Abcam, Cambridge, MA), mouse anti-Akt1 (Cell Signaling Technology, Beverly, MA), rabbit anti-phospho Akt ser473 (Cell Signaling Technology), rabbit anti-phospho-mTOR ser2448 (Cell Signaling Technology), rabbit anti-phospho GSK3
/
(Cell Signaling Technology), rabbit anti-Bcl-2 (BD Biosciences PharMingen), and mouse anti-actin (Sigma-Aldrich). Secondary antibodies used were anti-rabbit horseradish peroxidase (HRP) (Cell Signaling Technology), anti-mouse HRP (BD Biosciences PharMingen), Alexa Fluor 680 anti-rabbit IgG (Invitrogen), and IR Dye 800 anti-mouse IgG (LI-COR Biosciences, Lincoln, NE). Secondary antibodies consisting of HRP were viewed by ECL-Plus (GE Healthcare, Little Chalfont,, Buckinghamshire, United Kingdom), and secondary antibodies conjugated with fluorophores were scanned with LI-COR Odyessy (LI-COR Biosciences).
| RESULTS |
|---|
|
|
|---|
|
Glut1 Internalization and Recycling Are Growth Factor Regulated
In addition to synthesis of new Glut1 protein, IL3 may regulate Glut1 surface levels through effects on Glut1 internalization or recycling of internalized Glut1 back to the cell surface. To begin to dissect how IL3 may regulate Glut1 surface levels, we performed a pulse-chase assay to directly measure the internalization of labeled Glut1 proteins by flow cytometry. Cells stably expressing FLAG-Glut1 were cultured in the presence or absence of IL3, stained with anti-FLAG antibody, and washed free of unbound antibody. Remaining surface Glut1 staining was then measured by addition of secondary antibody after various times in culture. Cell surface FLAG-Glut1 staining at each time point was normalized to the level of staining at the starting time point to determine the percentage of labeled Glut1 protein that was retained on the cell surface over time (Figure 2A). Surface Glut1 decreased more rapidly in cytokine-deprived cells, suggesting that IL3 regulated Glut1 internalization in addition to possible effects on Glut1 efflux to the cell surface.
|
Cytokine-mediated Activation of the PI3K Pathway Is Necessary to Maintain Maximal Cell Surface Levels of Glut1
IL3 may regulate Glut1 trafficking through a number of signaling pathways (Fox et al., 2003
; Rathmell et al., 2003
). Among these, activation of the PI3K pathway and its downstream effector kinase Akt have been shown to promote cell surface trafficking of Glut4 (Welsh et al., 2005
) and to increase expression and cell surface levels of Glut1 (Piper et al., 1991
) in response to insulin stimulation. We found that endogenous PI3K pathway activity was necessary for growth factor to stimulate maximal cell surface Glut1, because treatment of FLAG-Glut1expressing cells with the PI3K inhibitor LY294002 reduced surface Glut1 levels in the presence of IL3 (Figure 3A). No difference in surface FLAG-Glut1 levels was observed when LY294002 was added at the time of IL3-withdrawal, an occasion when endogenous PI3K was inactive. Importantly, LY294002 had no effect on total levels of FLAG-Glut1 protein at these time points, suggesting that LY294002 was not altering surface Glut1 levels via changes in Glut1 synthesis or degradation (Figure 3B). Rather, inhibition of PI3K seemed to lead to a failure of IL3 to promote Glut1 protein localization to the cell surface.
|
Activated Akt Promotes Glucose Uptake and Maintains Surface Glut1 upon Growth Factor Withdrawal
Akt is a major mediator of many PI3K-induced signals that can promote both glucose metabolism and Glut1 expression (Barthel et al., 1999
; Plas et al., 2001
). We next sought to characterize IL3 activation of Akt and to determine whether Akt could also regulate glucose uptake in hematopoietic cells. Stimulation of growth factor-deprived FL5.12 cells with IL3 induced a robust initial phosphorylation of endogenous Akt followed by a lower chronic level of phospho-Akt that became apparent between 30 and 60 min after IL3 addition (Figure 4A). Transient transfection of FL5.12 cells with a myristoylated and constitutively active oncogenic form of Akt (myrAkt) mimicked initial high levels of IL3-induced Akt phosphorylation both in the presence and absence of IL3 (Figure 4B). Phospho-Akt levels were indicative of Akt activity, because mTOR phosphorylation was enhanced in the presence of IL3 and expression of myrAkt was able to maintain this phosphorylation even in the absence of IL3.
|
Akt Activation of mTOR/RAPTOR Does Not Affect Glut1 Trafficking but Does Regulate Glut1 Transporter Activity
To determine the mechanism of Akt-mediated regulation of glucose uptake and Glut1, we next analyzed the role of specific Akt substrates on Glut1. Akt has previously been shown to affect the localization of several nutrient transporters in hematopoietic cells, including the TfR. Regulation of surface TfR levels by Akt was rapamycin sensitive and dependent on the mTOR/RAPTOR complex (Edinger and Thompson, 2002
). We sought, therefore, to determine whether the Akt pathway for regulation of Glut1 localization in hematopoietic cells was regulated by mTOR/RAPTOR. Previously, myrAkt regulation of TfR had been most clearly demonstrated after 1-d IL3 withdrawal (Edinger and Thompson, 2002
). To prevent cell death and allow analysis of surface FLAG-Glut1 at this time point for best comparison with regulation of TfR, the antiapoptotic protein Bcl-xL was expressed in control cells. The myrAkt itself was antiapoptotic and prevented cell death similar to Bcl-xL (data not shown). Bcl-xL expression had no effect on TfR or Glut1 trafficking in cytokine withdrawal (Rathmell et al., 2000
; Edinger and Thompson, 2002
). Surface levels of both TfR and Glut1 were reduced significantly in IL3-withdrawn Bcl-xL-expressing cells compared with cells that expressed myrAkt, which maintained high levels of both TfR and Glut1 in IL3 withdrawal (Figure 5, A and B). Levels of surface TfR and Glut1 in myrAkt expressing cells were comparable with levels observed in the presence of IL3 (data not shown). As reported, treatment of myrAkt cells with rapamycin led to a substantial decrease in surface TfR levels (Figure 5A) (Edinger and Thompson, 2002
). Surface and total levels of FLAG-Glut1, however, were unaffected by rapamycin (Figure 5, B and C). These data show that Akt-mediated regulation of both surface and total Glut1 levels is mTOR/RAPTOR independent and is mediated by a pathway distinct from that of TfR.
|
Inactivation of GSK3 Promotes Glut1 Cell Surface Localization but Does Not Alter Glut1 Internalization
Another important Akt substrate that may affect Glut1 trafficking is GSK3. In this case, Akt phosphorylation of GSK3 leads to inhibition rather than activation of kinase activity (Jope and Johnson, 2004
). Because GSK3 has recently been shown to inhibit recycling of internalized
v
3 and
5
1 integrins back to the cell surface (Roberts et al., 2004
), we sought to determine whether Akt-mediated inhibition of GSK3 may play a role to increase surface Glut1 levels. Stimulation of cells with IL3 led to inhibitory phosphorylation of GSK3 and expression of myrAkt was sufficient to sustain this inhibitory phosphorylation even in the absence of IL3 (Figure 6A). Treatment of cells with the GSK3 inhibitor compound SB216763 both prevented this phosphorylation and prevented GSK3 kinase activity. Inhibition of GSK3 did not affect total cellular expression of FLAG-Glut1 (Figure 6A). Similar to expression of myrAkt, treatment of cells with the GSK3 inhibitor during IL3-withdrawal did, however, largely maintain Glut1 cell surface levels (Figure 6B; p < 0.005). Similar results also were obtained with the GSK3 inhibitors SB415286 and AR-A0144-18 (data not shown).
|
Akt Promotes Glut1 Surface Localization via Attenuating Glut1 Internalization in Absence of Growth Factor
In addition to promoting recycling of internalized Glut1 through inhibition of GSK3, Akt may also regulate Glut1 endocytosis. We sought to determine, therefore, whether Akt required efficient Rab11a-mediated recycling and inhibition of GSK3 to maintain surface Glut1. Cells stably expressing FLAG-Glut1 were transiently transfected with control, myrAkt, dnRab11a, or both myrAkt and dnRab11a. Surface FLAG-Glut1 levels were measured by flow cytometry after a 6-h growth factor withdrawal (Figure 7A). The myrAkt maintained surface expression of FLAG-Glut1 in the absence of IL3 even when endocytic recycling of Glut1 was blocked with dnRab11a. Furthermore, myrAkt was capable of largely maintaining surface Glut1 even in the presence of activated GSK3 (Figure 7B). Transfection of constitutively active form of GSK3 (GSK3 S9A) reduced surface levels of FLAG-Glut1 in control cells even in the presence of IL3 (p < 0.05). In cells expressing myrAkt, however, GSK3 S9A caused only a modest decrease in surface Glut1 that was maintained upon cytokine withdrawal. This suggested that myrAkt regulated Glut1 through pathways in addition to and upstream or dominant to those regulated by GSK3, such as would occur if Akt also prevented Glut1 internalization. To directly test whether activated Akt could prevent Glut1 endocytosis upon growth factor withdrawal, we used a pulse-chase assay to directly measure internalization of Glut1. Cells stably expressing FLAG-Glut1 were transfected with either control or myrAkt and cultured in the presence or absence of IL3 for 6 h followed by the pulse-chase assay (Figure 7C). Indeed, myrAkt was sufficient to attenuate Glut1 internalization in the absence of IL3. Together, these data indicate that Akt promotes maximal levels of surface Glut1 by both attenuating endocytosis and promoting recycling of Glut1.
|
| DISCUSSION |
|---|
|
|
|---|
In insulin-responsive tissues, Glut4 trafficking has been widely described to regulate acute glucose uptake, and although some aspects of Glut1 regulation described here may be shared with Glut4, others are distinct. Glut4 has been known to undergo rapid translocation from intracellular storage vesicles to the cell surface in response to insulin in insulin-responsive tissues (Welsh et al., 2005
). Glut1 also responds to insulin by accumulation on the cell surface in these cell types, albeit to a lower extent and at a much slower rate than Glut4 (Piper et al., 1991
). Akt regulates surface trafficking of both Glut4 and Glut1, with Akt2-mediated phosphorylation of AS160 (Zeigerer et al., 2004
; Larance et al., 2005
; Gonzalez and McGraw, 2006
) critical to promote Glut4 translocation. Mechanisms by which insulin-stimulated Akt activity may regulate Glut1 are less certain, but they may include mechanisms described here. Our results demonstrate that Glut1 cell surface trafficking is not unique to insulin; it also occurs in response to growth factor and oncogenic stimulation in noninsulin-responsive tissues. A key difference between IL3-mediated trafficking of Glut1 to the cell surface and insulin-induced Glut4 trafficking in insulin-responsive tissues is that Glut4 is present in storage vesicles poised to respond to insulin and traffic to the cell surface. Glut1, in contrast, must be synthesized for delivery to the cell surface or returned to the cell surface through a recycling pool. Thus, Glut4 translocation provides for rapid glucose uptake for acute use, whereas Glut1 trafficking is slower and allows glucose uptake in chronic conditions, such as required for cell growth. Because both Glut1 and Glut4 are insulin responsive, defining shared and distinct mechanisms in regulation of Glut1 and Glut4 trafficking will aid in understanding insulin-regulated glucose homeostasis.
In addition to promoting Glut1 expression (Barthel et al., 1999
; Plas et al., 2001
), we provide direct evidence with cell surface staining that Akt maintains Glut1 protein on the surface even upon growth factor withdrawal. Akt has also been shown to promote surface accumulation of nutrient transporters such as amino acid, LDL, and transferrin receptors (Edinger and Thompson, 2002
). In these cases, the inhibitor of the mTOR/RAPTOR complex, rapamycin, blocked Akt-mediated regulation of nutrient transporter localization. In contrast, our results with IL3 stimulation and Akt are similar to what has been reported in 3T3-L1 adipocytes (Tremblay et al., 2005
), where insulin-stimulated Glut1 translocation to cell surface was reported to be insensitive to rapamycin treatment (Figure 5B). These data indicate that Akt regulates Glut1 surface localization differently than other nutrient transporters. It remains unclear how this selective trafficking of Glut1 is regulated.
Despite the inability of mTOR/RAPTOR inhibition to alter Glut1 protein levels or localization, rapamycin lead to a sharp reduction in glucose uptake. These data suggest that mTOR/RAPTOR may affect Glut1 transporter activity. Glut1 activity can be regulated by intracellular ATP binding, which increases glucose transport activity by modulating substrate binding affinity (Levine et al., 1998
; Lachaal et al., 2001
; Liu et al., 2001
). Glycosylation of Glut1 has also been suggested to increase Glut1 glucose transport activity (Asano et al., 1991
). Modulation of Glut1 transport activity by signaling components, however, is not completely understood. In principle, mTOR/RAPTOR may regulate Glut1 activity through either of these pathways by modulation of downstream metabolism to promote ATP generation or by altering protein glycosylation patterns. Alternatively, mTOR/RAPTOR can affect a variety of other cellular processes that may impact Glut1 activity. Although our data do not distinguish between direct or indirect mechanisms of mTOR/ RAPTOR regulation of Glut1 activity, Tremblay et al. (2005)
showed that acute inhibition of mTOR/RAPTOR led to increased insulin-stimulated glucose uptake rather than the decreased glucose uptake observed here using longer treatments of rapamycin. Together, these findings suggest that either mTOR/RAPTOR has differential effects on Glut4 and Glut1 or that rapamycin's inhibition of glucose uptake occurs only after chronic mTOR/RAPTOR inhibition. Because mTOR/ RAPTOR inhibitors are becoming increasingly used in a variety of clinical settings, it will be particularly important to further study this novel function of mTOR/RAPTOR on glucose uptake and glucose transporter activity.
In addition to Glut1 activity, glucose uptake is regulated through the net efflux and influx of Glut1 proteins from the cell surface and Akt regulated this balance through GSK3 dependent and independent means. Akt can directly phosphorylate GSK3
/
on serines 21/9 to inhibit GSK3 kinase activity (Jope and Johnson, 2004
) and maintain surface Glut1 levels even in the absence of IL3. This maintenance of surface Glut1 by GSK3 inhibition was likely due to enhanced efflux of Glut1 relative to control cells, as Glut1 influx was not altered by GSK3. These data are consistent with results from Roberts et al. (Roberts et al., 2004
), who recently demonstrated that inhibition of GSK3 lead to enhanced recycling of integrins. Akt did not, however, require GSK3 inhibition or Rab11a-dependent recycling to maintain surface Glut1 levels as Akt also attenuated Glut1 internalization, thus obviating a requirement for maximal recycling activity to maintain surface Glut1. The mechanism by which Akt regulates Glut1 endocytosis is not clear, but does not appear to involve mTOR/RAPTOR or GSK3.
Here, we show that Glut1 trafficking is a regulated event that is critical in growth factor-regulated glucose homeostasis, and we define three distinct mechanisms by which Akt may promote glucose uptake. Activation of the proapoptotic molecule Bax and programmed cell death occurs if sufficient levels of glucose are not maintained in immune cells or during development (Moley and Mueckler, 2000
; Rathmell et al., 2003
). Conversely, increased glucose uptake occurs in immune cell activation and in poor prognosis cancers and is required for increased cellular proliferation (Gatenby and Gillies, 2004
; Macheda et al., 2005
). We demonstrate that growth factors and oncogenic Akt regulate Glut1 activity and trafficking. It will be important in future studies to further define these pathways to determine how growth factors and oncogenes promote sufficient glucose uptake to match intracellular demands to allow cell growth and to prevent cell death.
| ACKNOWLEDGMENTS |
|---|
| Footnotes |
|---|
Address correspondence to: Jeffrey C. Rathmell (jeff.rathmell{at}duke.edu)
Abbreviations used: 2-DOG, 2-deoxy-D-glucose; CHX, cycloheximide; GFP, green fluorescent protein; GSK, glycogen synthase kinase 3; HRP, horseradish peroxidase; IL, interleukin; LDL, low-density lipoprotein; myrAkt, myristoylated Akt; PBS, phosphate-buffered saline; PI3K, phosphatidylinositol 3-kinase; TfR, transferrin receptor.
| REFERENCES |
|---|
|
|
|---|
Barnes, K., McIntosh, E., Whetton, A. D., Daley, G. Q., Bentley, J., Baldwin, S. A. (2005). Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 24, 32573267.[CrossRef][Medline]
Barthel, A., Okino, S. T., Liao, J., Nakatani, K., Li, J., Whitlock, J. P. Jr, Roth, R. A. (1999). Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J. Biol. Chem 274, 2028120286.
Bentley, J., Itchayanan, D., Barnes, K., McIntosh, E., Tang, X., Downes, C. P., Holman, G. D., Whetton, A. D., Owen-Lynch, P. J., Baldwin, S. A. (2003). Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J. Biol. Chem 278, 3933739348.
Cham, C. M. and Gajewski, T. F. (2005). Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J. Immunol 174, 46704677.
Ciofani, M. and Zuniga-Pflucker, J. C. (2005). Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat. Immunol 6, 881888.[CrossRef][Medline]
Cong, L. N., Chen, H., Li, Y., Zhou, L., McGibbon, M. A., Taylor, S. I., Quon, M. J. (1997). Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol. Endocrinol 11, 18811890.
Dang, C. V. (1999). c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell Biol 19, 111.[Medline]
Deshmukh, M., Vasilakos, J., Deckwerth, T. L., Lampe, P. A., Shivers, B. D., Johnson, E. M. Jr. (1996). Genetic and metabolic status of NGF-deprived sympathetic neurons saved by an inhibitor of ICE family proteases. J. Cell Biol 135, 13411354.
Edinger, A. L. and Thompson, C. B. (2002). Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 22762288.
Foran, P. G., Fletcher, L. M., Oatey, P. B., Mohammed, N., Dolly, J. O., Tavare, J. M. (1999). Protein kinase B stimulates the translocation of GLUT4 but not GLUT1 or transferrin receptors in 3T3L1 adipocytes by a pathway involving SNAP-23, synaptobrevin-2, and/or cellubrevin. J. Biol. Chem 274, 2808728095.
Fox, C. J., Hammerman, P. S., Cinalli, R. M., Master, S. R., Chodosh, L. A., Thompson, C. B. (2003). The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 17, 18411854.
Frauwirth, K. A. and Thompson, C. B. (2004). Regulation of T lymphocyte metabolism. J. Immunol 172, 46614665.
Gatenby, R. A. and Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891899.
Gonzalez, E. and McGraw, T. E. (2006). Insulin signaling diverges into Akt-dependent and -independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Mol. Biol. Cell 17, 44844493.
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., Hay, N. (2001). Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15, 14061418.
Heilig, C. W., Saunders, T., Brosius, F. C. 3rd, Moley, K., Heilig, K., Baggs, R., Guo, L., Conner, D. (2003). Glucose transporter-1-deficient mice exhibit impaired development and deformities that are similar to diabetic embryopathy. Proc. Natl. Acad. Sci. USA 100, 1561315618.
Jope, R. S. and Johnson, G. V. (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci 29, 95102.[CrossRef][Medline]
Kan, O., Baldwin, S. A., Whetton, A. D. (1994). Apoptosis is regulated by the rate of glucose transport in an interleukin 3 dependent cell line. J. Exp. Med 180, 917923.
Kandel, E. S. and Hay, N. (1999). The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res 253, 210229.[CrossRef][Medline]
Kansara, M. and Berridge, M. V. (2004). Oncogenes modulate cell sensitivity to apoptosis induced by glucose deprivation. Anticancer Res 24, 25032510.[Medline]
Krauss, S., Brand, M. D., Buttgereit, F. (2001). Signaling takes a breathnew quantitative perspectives on bioenergetics and signal transduction. Immunity 15, 497502.[CrossRef][Medline]
Lachaal, M., Spangler, R. A., Jung, C. Y. (2001). Adenosine and adenosine triphosphate modulate the substrate binding affinity of glucose transporter GLUT1 in vitro. Biochim. Biophys. Acta 1511, 123133.[Medline]
Larance, M., et al. (2005). Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking. J. Biol. Chem 280, 3780337813.
Levine, K. B., Cloherty, E. K., Fidyk, N. J., Carruthers, A. (1998). Structural and physiologic determinants of human erythrocyte sugar transport regulation by adenosine triphosphate. Biochemistry 37, 1222112232.[CrossRef][Medline]
Lin, S. X., Grant, B., Hirsh, D., Maxfield, F. R. (2001). Rme-1 regulates the distribution and function of the endocytic recycling compartment in mammalian cells. Nat. Cell Biol 3, 567572.[CrossRef][Medline]
Liu, Q., Vera, J. C., Peng, H., Golde, D. W. (2001). The predicted ATP-binding domains in the hexose transporter GLUT1 critically affect transporter activity. Biochemistry 40, 78747881.[CrossRef][Medline]
Macheda, M. L., Rogers, S., Best, J. D. (2005). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol 202, 654662.[CrossRef][Medline]
Maxfield, F. R. and McGraw, T. E. (2004). Endocytic recycling. Nat. Rev. Mol. Cell Biol 5, 121132.[CrossRef][Medline]
Moley, K. H. and Mueckler, M. M. (2000). Glucose transport and apoptosis. Apoptosis 5, 99105.[CrossRef][Medline]
Piper, R. C., Hess, L. J., James, D. E. (1991). Differential sorting of two glucose transporters expressed in insulin-sensitive cells. Am. J. Physiol 260, C570C580.[Medline]
Plas, D. R., Rathmell, J. C., Thompson, C. B. (2002). Homeostatic control of lymphocyte survival: potential origins and implications. Nat. Immunol 3, 515521.[CrossRef][Medline]
Plas, D. R., Talapatra, S., Edinger, A. L., Rathmell, J. C., Thompson, C. B. (2001). Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J. Biol. Chem 276, 1204112048.
Rathmell, J. C., Farkash, E. A., Gao, W., Thompson, C. B. (2001). IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol 167, 68696876.
Rathmell, J. C., Fox, C. J., Plas, D. R., Hammerman, P. S., Cinalli, R. M., Thompson, C. B. (2003). Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell Biol 23, 73157328.
Rathmell, J. C., Vander Heiden, M. G., Harris, M. H., Frauwirth, K. A., Thompson, C. B. (2000). In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol. Cell 6, 683692.[CrossRef][Medline]
Roberts, M. S., Woods, A. J., Dale, T. C., Van Der Sluijs, P., Norman, J. C. (2004). Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol. Cell Biol 24, 15051515.
Thompson, J. E. and Thompson, C. B. (2004). Putting the rap on Akt. J. Clin. Oncol 22, 42174226.
Tremblay, F., Gagnon, A., Veilleux, A., Sorisky, A., Marette, A. (2005). Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3L1 and human adipocytes. Endocrinology 146, 13281337.
Ullrich, O., Reinsch, S., Urbe, S., Zerial, M., Parton, R. G. (1996). Rab11 regulates recycling through the pericentriolar recycling endosome. J. Cell Biol 135, 913924.
Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T., Thompson, C. B. (1997). Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 91, 627637.[CrossRef][Medline]
Vander Heiden, M. G., Plas, D. R., Rathmell, J. C., Fox, C. J., Harris, M. H., Thompson, C. B. (2001). Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol. Cell Biol 21, 58995912.
Warburg, O. (1956). On the origin of cancer cells. Science 123, 309314.
Watson, R. T., Kanzaki, M., Pessin, J. E. (2004). Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocr. Rev 25, 177204.
Welsh, G. I., Hers, I., Berwick, D. C., Dell, G., Wherlock, M., Birkin, R., Leney, S., Tavare, J. M. (2005). Role of protein kinase B in insulin-regulated glucose uptake. Biochem. Soc. Trans 33, 346349.[CrossRef][Medline]
Zeigerer, A., McBrayer, M. K., McGraw, T. E. (2004). Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol. Biol. Cell 15, 44064415.
This article has been cited by other articles:
![]() |
N. J. MacIver, S. R. Jacobs, H. L. Wieman, J. A. Wofford, J. L. Coloff, and J. C. Rathmell Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival J. Leukoc. Biol., October 1, 2008; 84(4): 949 - 957. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Buller, R. D. Loberg, M.-H. Fan, Q. Zhu, J. L. Park, E. Vesely, K. Inoki, K.-L. Guan, and F. C. Brosius III A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression Am J Physiol Cell Physiol, September 1, 2008; 295(3): C836 - C843. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Borthakur, R. K. Gill, S. Tyagi, A. Koutsouris, W. A. Alrefai, G. A. Hecht, K. Ramaswamy, and P. K. Dudeja The Probiotic Lactobacillus acidophilus Stimulates Chloride/Hydroxyl Exchange Activity in Human Intestinal Epithelial Cells J. Nutr., July 1, 2008; 138(7): 1355 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Jacobs, C. E. Herman, N. J. MacIver, J. A. Wofford, H. L. Wieman, J. J. Hammen, and J. C. Rathmell Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways J. Immunol., April 1, 2008; 180(7): 4476 - 4486. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Wofford, H. L. Wieman, S. R. Jacobs, Y. Zhao, and J. C. Rathmell IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival Blood, February 15, 2008; 111(4): 2101 - 2111. [Abstract] [Full Text] [PDF] |
||||